Studying people who live unusually long with pancreatic cancer, glioblastoma or small-cell lung cancer
Compares tumor samples and records of long-term and typical survivors in 3 cancers.
Key facts
- Who runs it
- Cure 51
- Where
- Villejuif, FranceSee the site
- Trial code
- Registry title
- Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis
- Status
- Recruiting
- People taking part
- 1,020 people, planned
- Started
- 1 Nov 2023
- Expected to end
- 1 May 2028
- Type of study
- Observational, 3 groups
- Treatments tested
- Long term survival multimodal analysis
- Record updated
- 7 December 2023
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with metastatic pancreatic cancer, glioblastoma IDHwt or extensive small cell lung cancer. It includes both exceptionally long-term survivors and control patients with standard survival.
- Age
- 18 years or older at diagnosis.
- Sex
- All sexes can join.
- Disease stage
- Metastatic pancreatic ductal adenocarcinoma, glioblastoma IDHwt, or extensive small cell lung cancer. Long survivors: at least 5 years from stage IV diagnosis for pancreatic and small cell lung cancer, at least 3 years for glioblastoma.
- Earlier treatment
- All prior treatments are accepted, but any treatment before the tumor sample was taken must be reported.
- Biomarker or test result
- A tumor sample of enough quality and quantity for multi-omic analyses must be available. Samples should be at least 5 years old for pancreatic and small cell lung cancer, and 3 years old for glioblastoma.
Main reasons for not taking part
- Younger than 18 years at diagnosis
- Blood cancers or solid tumors of other types
- Tumor sample not available or of too low quality for multi-omic analyses
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- FOR SURVIVORS
- To be eligible the exceptional survivor patients must fulfill the following inclusion criteria:; Adult patient (≥18 years old at diagnosis); Three distinct cohorts, one of patients harbouring metastatic pancreatic ductal adenocarcinoma, glioblastoma IDHwt, extensive small cell lung cancer; Long-term survival is defined as an exceptionally long survival ≥ 5 years from stage IV diagnosis for PDAC, extensive SCLC, and ≥ 3 years for GBM-IDHwt; Availability of at least one block sample and associated clinical annotations with following characteristics:; One block sample must be of sufficient quality and in sufficient quantity to perform multi-omic analyses, according to requirements specified in Lab manual; Any treatment prior to sample acquisition must be reported - all treatments accepted (standard / targeted); Samples should be at least 5 years old for PDAC and SCLC and 3 years old for GBM; For CONTROL GROUPS :
- To be eligible the control patients must fulfill the following inclusion criteria:; ≥18 years old at diagnosis; Three distinct cohorts, one of patients suffering from metastatic pancreatic ductal adenocarcinoma, one for glioblastoma, one for extensive small cell lung cancer; Paired to long-term survivors as mentioned in the methodology section; Death or median overall survival with a variation of 10% before of beyond as reported in pivotal clinical trials in the specific type disease; Availability of at least one tumor sample and associated clinical annotations with following characteristics:; Sample must be of sufficient quality and in sufficient quantity to perform multi-omic analyses; Any treatment prior to sample acquisition must be reported (treatment-naive samples should be preferred) - all treatments accepted (standard / targeted)
Who cannot take part
- Patient must not be enrolled if he/she fulfils one of the following non-inclusion criteria:; <18 years old at diagnosis; Hematological malignancy or solid tumors, which are not in the scope of tumor types, described in the inclusion criteria; Tumor sample not available or not reaching the required quality for multi-omic analyses
Where in France
- Gustave Roussy Cancer Campus, Grand ParisVillejuif, FranceContact: Julieta Rodriguez, MDTaking people
About the trial
What the trial wants to find out
This is a retrospective, exploratory, multi-center, translational, 3 cohorts case control matched study conducted in patients harboring a solid tumor with poor prognosis who presented a long-term (case) and standard (standard) survival.
Read full original descriptionShow less
Patients with:
* Cohort A: metastatic pancreatic ductal adenocarcinoma * Cohort B: glioblastoma IDHwt * Cohort C: extensive small cell lung cancer
This research aims to integrate data generated from clinical records, imaging, multi-omics and bioinformatics approaches to discriminate case and control and then to identify new therapeutic targets. Analyses will be performed depending on the tumor samples available with at least 3 omics levels and according to scientific advances; genomic, epigenomic, proteomics, metabolomics, transcriptomic, microbiomic.
The 3 groups in the trial
- PDAC STAGE IV SURVIVORS & CONTROLS
Metastatic pancreatic ductal adenocarcinoma (PDAC) (Other histologies such as adenosquamous carcinoma, hepatoid carcinoma, anaplastic undifferentiated carcinoma and medullary carcinoma, acinar cell carcinoma, neuroendocrine tumors, Solid pseudopapillary neoplasm, Pancreatoblastoma, Serous cystadenocarcinoma are excluded)
Treatment: Long term survival multimodal analysis
- SMALL CELL LUNG CANCER EXTENSIVE STAGE SURVIVORS & CONTROLS
Extensive small cell lung cancer (SCLC) (Other histologies excluded: combined SCLC with some areas of non-small cell lung cancer (NSCLC), carcinoid tumors, typical and atypical, large cell neuroendocrine carcinoma of the lung).
Treatment: Long term survival multimodal analysis
- GLIOBLASTOMA SURVIVORS & CONTROLS
Glioblastoma (GBM) (IDH mutated excluded)
Treatment: Long term survival multimodal analysis
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis: A 3 Cohorts Case Control Matched Study
- Plain-language title
- Studying people who live unusually long with pancreatic cancer, glioblastoma or small-cell lung cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 7 December 2023